1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
SOHO 2026 Annual Meeting
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
MDS - 583
ATLAS: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Seamless Phase 2/3 Study to Assess the Safety and Efficacy of Momelotinib in Patients With VEXAS Syndrome
Poster Presenter
Authors
Part of Topic
Myelodysplastic Syndromes (MDS)
ATLAS: A randomized, double-blind, placebo-controlled, adaptive seamless phase 2/3 study to assess the safety and efficacy of momelotinib in patients with VEXAS syndrome